Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology
Xiaoxuan LiJianming Wu

Abstract

Background: Teneligliptin is a 3rd-generation dipeptidyl peptidase-4 (DPP-4) inhibitor. There is a limited evidence regarding the effect of teneligliptin. Therefore, this study is to assess the efficacy and safety of teneligliptin in type 2 diabetes mellitus (T2DM) patients with inadequately glycemic controlled. Methods: A search of PubMed, Medline, Embase, and The Cochrane Library during 2000.01-2018.03 was performed for randomized controlled trials of teneligliptin compared to placebo in patients with T2DM with monotherapy or add-on treatment. Results: Ten trials with 2119 patients were analyzed. Teneligliptin produced absolute reductions in glycated hemoglobin A1c (HbA1c) levels (weighted mean difference (WMD) 0.82%, 95% confidence interval (CI) [-0.91 to -0.72], p < 0.00001) compared with placebo. However, after 36-42 weeks of follow-up (open-label), HbA1c level rise higher than duration (double-blind) in teneligliptin group. Teneligliptin led to greater decrease of fasting plasma glucose (FPG) level (vs. placebo, WMD -18.32%, 95% CI [-21.05 to -15.60], p < 0.00001). Teneligliptin also significantly decreased the 2 h post-prandial plasma glucose (2 h PPG) (WMD -46.94%, 95% CI [-51.58 to -42.30], p < 0.00001) and area under ...Continue Reading

References

May 27, 2004·Diabetes Care·Tara M WallaceDavid R Matthews
Feb 5, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Baptist Gallwitz
Sep 25, 2012·The American Journal of Medicine·Emilia Pauline Liao
Mar 19, 2013·Biochemical and Biophysical Research Communications·Mika NabenoTakashi Kadowaki
May 15, 2013·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Miyako Kishimoto
Feb 11, 2014·Diabetes/metabolism Research and Reviews·Shlomit Koren, Micha J Rapoport
Apr 22, 2014·Expert Opinion on Drug Metabolism & Toxicology·Theodosios D FilippatosMoses S Elisaf
May 21, 2014·Journal of Diabetes Investigation·Takashi Kadowaki, Kazuoki Kondo
Jun 3, 2014·Journal of Clinical Medicine Research·Eiji KutohYu Ikeno
Jan 20, 2015·Expert Opinion on Pharmacotherapy·Ryuichi Morishita, Hironori Nakagami
Apr 17, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberMichael H Davidson
Oct 18, 2015·Clinical Drug Investigation·Lesley J Scott
May 10, 2016·Expert Opinion on Pharmacotherapy·Xueying Tan, Jingbo Hu
Jul 29, 2016·Expert Opinion on Pharmacotherapy·Philip M S Evans, Stephen C Bain
Aug 31, 2016·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Surendra Kumar SharmaOnkar C Swami
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association
Feb 14, 2017·Lancet·Sudesna ChatterjeeMelanie J Davies
Mar 10, 2017·Journal of Clinical and Diagnostic Research : JCDR·Mohammed AbubakerOnkar C Swami
Mar 16, 2017·Trends in Cardiovascular Medicine·Matthew H SecrestKristian B Filion
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Feb 21, 2018·Current Opinion in Genetics & Development·Paul W Franks, Jordi Merino

❮ Previous
Next ❯

Citations

May 13, 2020·Journal of Diabetes·Margaret F BassendineMark D Gorrell
Aug 12, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sujoy GhoshVijay Panikar

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00998881

Software Mentioned

GRADE
Cochrane

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.